BridgeBio’s Attruby outperforms sales expectations, shares rise

Elizabeth Cairns

Senior biopharma journalist

When BridgeBio reported Attruby prescription numbers in February, the figures came in substantially above analyst projections. Now the company has pulled off …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio’s Attruby outperforms sales expectations, shares rise

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

Scientists alarmed about future of cancer research; TIGIT, CAR-NK and more from #AACR25

GSK's supply chain 'reset' after Haleon spinoff to ease tariff impact, CEO says

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Bridge­Bio’s At­tru­by out­per­forms sales ex­pec­ta­tions, shares rise

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

BridgeBio’s Attruby outperforms sales expectations, shares rise